ยาต้านวัณโรค,อาการไม่พึงประสงค์ทางผิวหนัง,อุบัติการณ์,ลักษณะทางคลินิก,วิธีการ รักษา Objectives: 1). To study the incidence of antituberculosis drug-induced cutaneous adverse drug reactions (antiTB-CADRs); 2). To study the clinical characteristics (type, severity, onset) of antiTB-CADRs; 3). To compare the outcome of different management methods for mild and moderate antiTB-CADRs; 4) To study management methods for severe antiTB-CADRs; 5) To study the rechallenge methods for severe antiTB-CADRs; 6). To compare TB treatment outcome between different methods for mild and moderate antiTB-CADRs; 7). To compare tuberculosis (TB) treatment outcome between patients with and without antiTB-CADRs Methodology: This was a prospective study conducted in 17 hospitals of 5 provinces of lower southern Thailand. New cases of tuberculosis patients aged not less than 18 years treated with first-line antituberculosis drugs were included. Patients were excluded if 1) they had abnormal skin conditions such as itching and/or rash before they started the treatment, and 2) they could not communicate in Thai. Antituberculosis drug-induced cutaneous adverse drug reaction (antiTB-CADR) was defined as a skin reaction such as rash and/or itching occurring during the treatment without other causes. At diagnosis, patients were informed about antiTB-CADR and to visit their attending physicians immediately if they experienced any cutaneous ADR. Moreover, they were followed up everyday within the first two week, then every week until the end of intensive phase. Clinical presentations associated with antiTB-CADR, including type, onset, and severity, were recorded. Additionally, antiTB-CADR management methods and their outcomes and TB treatment outcome were also documented. Results: Of the 700 TB patients included, the total followed up time for all patients until the end of intensive phase was 34,146 days and 121 patients experienced antiTB